Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epclusa in HCV- Liver Transplant Recipients from HCV+ Donors
NCT03819322Phase 2Completed
- Start
- Aug 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sofosbuvir + velpatasvir in hepatitis C (HCV) (2 arms). Primary endpoints: Adverse Events Due to Sofosbuvir/Velpatasvir (Epclusa) at 5 years and HCV Free at 1 Year Following Transplantation. Started Aug 2019; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03819322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819322.